<DOC>
	<DOC>NCT00729443</DOC>
	<brief_summary>The study is carried out in order to investigate safety, tolerability and pharmacokinetics after administrating single and fractionated doses of AZD3241 to healthy volunteers</brief_summary>
	<brief_title>Investigating Safety, Tolerability and Pharmakinetics When Giving Single and Fractionated Doses of AZD3241 to Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Provision of informed consent Body Mass Index (BMI) 19 to 30 kg/m2 inclusive Clinically normal physical findings, including BP, pulse rate, ECG and laboratory findings, as judged by the investigator Clinically significant illness within the 2 weeks prior to the administration of the investigational product Heart rate (resting, recumbent) &lt;50 bmp or &gt;85 bmp History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity as judged by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Single dose</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Safety of AZD3241</keyword>
	<keyword>tolerability of AZD3241</keyword>
</DOC>